France grants early access to Janssen's ibrutinib for CLL & MCL
This article was originally published in Scrip
Executive Summary
The French regulator, ANSM, has approved an early access program for Janssen's ibrutinib in the treatment of chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL), pending its approval via the EU's centralized procedure.